Sertraline
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Sertraline: Histrionic personality disorder (disease)
One-Sentence Summary
Sertraline is an SSRI antidepressant that has been marketed in Canada for many years. The TxGNN model predicts it may be useful for histrionic personality disorder, but the data compiled for this report contain no clinical trials and no publications on this condition. The prediction is therefore supported by the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Histrionic personality disorder (disease) |
| TxGNN Prediction Score | 0.9993 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 20) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Sertraline belongs to the SSRI class, which raises serotonin availability in the brain. It is widely used for mood and anxiety-spectrum conditions. Mechanistically, it could plausibly affect emotional instability, anxiety or depressive symptoms that sometimes accompany personality disorders.
This link is theoretical. Histrionic personality disorder is defined by long-standing patterns of emotionality and attention-seeking, not by a single symptom that an antidepressant is known to treat. No study retrieved for this report examines sertraline in this disorder. Any benefit would most likely come from treating co-occurring depression or anxiety rather than the personality pathology itself. The model score is a hypothesis-generating signal only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Sertraline is marketed in Canada, and all 20 licences in the local records are valid single-ingredient products. The table lists 5 of them. The local records do not give a dosage form or an approved-indication text for these licences.
| DIN | Product Name |
|---|---|
| 01962779 | ZOLOFT |
| 01962817 | ZOLOFT |
| 02132702 | ZOLOFT |
| 02240481 | TEVA-SERTRALINE |
| 02244840 | PMS-SERTRALINE |
Safety Considerations
- Drug Interactions: 100 interactions were identified in the interaction screening. Several are rated Major and need particular attention when co-prescribing:
- Bupropion
- Lorcaserin
- Diethylpropion
- Phentermine
- Dolasetron
- Palonosetron
- Eliglustat
Moderate-level interactions include:
- Acetylsalicylic acid
- Morphine
- Clarithromycin
- Famotidine
- Loperamide
- Several antidiabetic agents (e.g., glimepiride, chlorpropamide, insulin aspart)
Please refer to the Health Canada product monograph for the full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but no clinical trial or publication in the compiled data studies sertraline in histrionic personality disorder. The mechanistic rationale is indirect, so the evidence level is L5 (model prediction only).
To proceed, the following is needed:
- A literature and trial search specific to histrionic personality disorder, including any studies of SSRIs in cluster B personality disorders
- Mechanism-of-action data and a clear hypothesis for which symptom domain sertraline would target
- Warnings and contraindications from the Health Canada product monograph
- A safety plan covering the Major drug interactions above and use in patients with co-occurring psychiatric conditions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.